<b>Full Title</b><br> EIK1001-005: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer <br><br> <b>Study Treatment</b><br> Toll-Like Receptor 7 and 8 co-agonist, EIK1001 given in combination with chemotherapy and pembrolizumab <br><br> <b>Eligibility/Info</b><br> - Stage IV squamous or non-squamous non-small cell lung cancer<br> - No history of systemic therapy in the advanced/metastatic setting<br> - No actionable mutation <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br>